CStone Pharmaceuticals Showcases Breakthrough in Cancer Therapy

CStone Pharmaceuticals (HK:2616) has released an update.

CStone Pharmaceuticals has unveiled promising preclinical data for its innovative trispecific antibody, CS2009, at the SITC Annual Meeting. Designed to target PD-1, CTLA-4, and VEGFA, CS2009 shows superior anti-tumor activity and potential applicability across various cancer types. The company anticipates initiating first-in-human trials by early 2025, marking a significant step forward in cancer immunotherapy.

For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.